UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 8, 2016
MYOKARDIA, INC.
(Exact name of registrant as specified in its charter)
| | | | |
| Delaware | | 001-37609 | | 44-5500552 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (I.R.S. Employer Identification No.) |
333 Allerton Ave.
South San Francisco, CA 94080
(Address of principal executive offices, including zip code)
(650) 741-0900
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 7.01 | Regulation FD Disclosure |
On March 8, 2016, MyoKardia, Inc., a Delaware corporation (the “Company”), intends to deliver a corporate presentation at the Cowen and Company 36th Annual Health Care Conference at 10:40 a.m. EST, during which the Company will present certain slides (the “Presentation”). The Company is disclosing new preclinical animal data for its lead product candidate, MYK-461, in hypertrophic cardiomyopathy (HCM) felines and for its DCM-1 candidate in canines, and is providing an update on its Phase 1 clinical trials of MYK-461 in HCM patients. A copy of the Presentation is furnished hereto as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 7.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
| Item 9.01 | Financial Statements and Exhibits |
(d) Exhibits.
| | |
Exhibit No. | | Description |
| |
| 99.1 | | March 8, 2016 Company presentation at Cowen and Company 36th Annual Health Care Conference, furnished herewith |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | |
| Date: March 8, 2016 | | | | MyoKardia, Inc. |
| | | |
| | | | By: | | /s/ Steven Chan |
| | | | | | Steven Chan |
| | | | | | Vice President, Corporate Controller (principal financial and accounting officer) |
EXHIBIT INDEX
| | |
Exhibit
No. | | Description |
| |
| 99.1 | | March 8, 2016 Company presentation at Cowen and Company 36th Annual Health Care Conference, furnished herewith |
